Tislelizumab
2020-SR-264.A1
Phase 2 small_molecule completed
Quick answer
Tislelizumab for Bladder Urothelial Carcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Bladder Urothelial Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed